Journal of Clinical Endocrinology & Metabolism, Vol 80, 2077-2081, Copyright © 1995 by Endocrine Society

ARTICLES

Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies

EF Adams, T Lei, M Buchfelder, B Petersen and R Fahlbusch
Department of Neurosurgery, University of Erlangen-Nurnberg, Germany.

Gsp oncogenes are present in about 40% of somatotropinomas. They result in excessive cAMP production and have been proposed to be the cause of increased GH secretion. We have used in vitro cell culture to compare the biochemical characteristics of somatotropinomas with and without gsp oncogenes (gsp-positive and gsp-negative tumors, respectively). Of 30 somatotropinomas examined, 10 proved to be gsp positive, as determined by sequence analysis of DNA generated by the polymerase chain reaction. The somatostatin analog, octreotide, powerfully inhibited GH secretion by gsp-positive somatotropinomas, but had no effect on 8 of 13 gsp-negative tumors. Five of 20 gsp-negative and 4 of 10 gsp-positive tumors failed to respond to GHRH, whereas stimulatory effects ranging from 37-500% increases in GH secretion occurred in the remainder. However, strong stimulation (> 4-fold) occurred only in 5 of the gsp-negative tumors. The basal phosphatidylinositol turnover rate was elevated in about 25% of gsp-negative somatotropinomas. These results demonstrate similar and highly variable effects of GHRH on both types of somatotropinoma, whereas the absence of gsp oncogenes is often associated with resistance to octreotide. The phosphatidylinositol turnover data suggest that defects within this second messenger system may be present in a subset of somatotropinomas without gsp oncogenes.

This article has been cited by other articles:

				L. S. Weinstein, S. Yu, D. R. Warner, and J. Liu Endocrine Manifestations of Stimulatory G Protein {alpha}-Subunit Mutations and the Role of Genomic Imprinting Endocr. Rev., October 1, 2001; 22(5): 675 - 705. [Abstract] [Full Text] [PDF]

				A. Barlier, I. Pellegrini-Bouiller, G. Gunz, A. J. Zamora, P. Jaquet, and A. Enjalbert Impact of gsp Oncogene on the Expression of Genes Coding for Gs{alpha}, Pit-1, Gi2{alpha}, and Somatostatin Receptor 2 in Human Somatotroph Adenomas: Involvement in Octreotide Sensitivity J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2759 - 2765. [Abstract] [Full Text]

				J. Yasufuku-Takano, K. Takano, T. Takei, S. Fukumoto, A. Teramoto, K. Takakura, N. Yamashita, and T. Fujita Heterozygous gsp Mutation Renders Ion Channels of Human Somatotroph Adenoma Cells Unresponsive to Growth Hormone-Releasing Hormone Endocrinology, May 1, 1999; 140(5): 2018 - 2026. [Abstract] [Full Text]

				A. Barlier, G. Gunz, A. J. Zamora, I. Morange-Ramos, D. Figarella-Branger, H. Dufour, A. Enjalbert, and P. Jaquet Pronostic and Therapeutic Consequences of Gs{alpha} Mutations in Somatotroph Adenomas J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1604 - 1610. [Abstract] [Full Text]

				E. F. Adams, B. Huang, M. Buchfelder, A. Howard, R. G. Smith, S. D. Feighner, L. H. T. van der Ploeg, C. Y. Bowers, and R. Fahlbusch Presence of Growth Hormone Secretagogue Receptor Messenger Ribonucleic Acid in Human Pituitary Tumors and Rat GH3 Cells J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 638 - 642. [Abstract] [Full Text]